P1‐269: A 12‐week, double‐blind, placebo‐controlled, dose‐range finding study of CHF5074 in patients with mild cognitive impairment
Joel Ross(Eaton (United States)), Bruno P. Imbimbo(Chiesi (France)), Helen Cicirello, Dottie Norris, Mercedes Fernández(University of Ferrara), Jaron L. Winston(Specialty Materials (United States)), Luciana Giardino, Francesco Fiorentini(Nerviano Medical Sciences), E. Frigerio, Sanjiv Sharma, Daniela Casula
Cited by 0
Related Papers
Endocrine Disrupters: A Review of Some Sources, Effects, and Mechanisms of Actions on Behaviour and Neuroendocrine Systems
|Journal of Neuroendocrinology|2011|425
An Updated Review of Ciguatera Fish Poisoning: Clinical, Epidemiological, Environmental, and Public Health Management
|Marine Drugs|2017|336
Ciguatera Fish Poisoning: Treatment, Prevention and Management
|Marine Drugs|2008|256
TLR3 and TLR7 RNA Sensor Activation during SARS-CoV-2 Infection
|Microorganisms|2021|196
Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome
|Journal of Neuroscience|2010|190